{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000001","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.289324+00:00","generated_at":"2026-05-28T03:29:08.415318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)","bullets":["Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).","Active patients globally: 4,126 total on TTFields; 4,077 Optune Gio; 52 Optune Lua prescriptions for NSCLC.","Cash, cash equivalents and short-term investments $959.9M as of Dec 31, 2024.","FDA approved Optune Lua for metastatic NSCLC in Oct 2024; Phase 3 PANOVA-3 trial met primary endpoint in pancreatic cancer.","FY2025 revenue growth expected to align with Optune Gio active patient growth; US prior-period claims added $8.3M in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000001","json":"https://secwatch.observer/filing/0001645113-25-000001.json","markdown":"https://secwatch.observer/filing/0001645113-25-000001.md","text":"https://secwatch.observer/filing/0001645113-25-000001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/0001645113-25-000001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/nvcr-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:29:08.415318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}